Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Perinatal hypoxic-ischaemic encephalopathy occurs in one to three infants per 1000 term
births, and up to 12 000 infants are affected each year in the united state of America.
Hypoxic ischemic encephalopathy is not preventable in most cases, and therapies are limited.
Hypothermia improves outcomes and is the current standard of care. Yet clinical trials
suggest that 44% to 53% of infants who receive hypothermia will die or suffer moderate to
severe neurological disability. Therefore, novel neuroprotective therapies are urgently
needed to further reduce the rate and severity of neurodevelopmental disabilities resulting
from hypoxic ischemic encephalopathy.
Erythropoietin is a novel neuroprotective agent, with remarkable neuroprotective and
neuroregenerative effects in animals. Rodent and primate models of neonatal brain injury
support the safety and efficacy of multiple erythropoietin doses for improving histological
and functional outcomes after hypoxia-ischaemia.